Member Info for Retireby40

The vision and innovation means MWG will have a solution that I imagine will eventually be in the fabric is many countries water systems. Obviously it will be for current clients (Spain et al) but more to follow. I bet it’ll be best practice and the countries adopting it will fall like dominoes.

They promised an update on the US and one wasn’t except to say sales are on the up (from what?) and they need to increae their presence. Sounds iffy in the US and sales for the month excluding PHE deal were some £20m (if PHE pay £7/test but also included some forward sales for Cambridge lab) so US has surely done very little. Trump lives Roche who aren’t American but he wants US cos which is why the gov invested in HOLX (nasdaq) who will do 1-3m tests a week beginning next week in US antigen high throughput machines in 50 States. Major interview on CNBC FDA fast track so US market not that big for the smaller parties.

They’ll be getting weekly updates from the OEM and NCYT’s slice will be included in the sales/orders figures announced, its revenue and material so of course it’s included. I just don’t think they’ve gained traction hence they want more presence there and they didn’t really update as they said they would. Other US players are coming to the market will gov funding so I doubt NCYT will generate too much from there. Let’s see but I think the rest of the world is a lot more important and easier to penetrate.

Development of a BAMS test capable of diagnosing whether a person has the COVID-19 infection at any specific moment is a rapid process and the two companies are aiming to have a final version ready for clinical validation, regulatory approval and manufacturing in June. Adeptrix and Avacta are already in discussion with large-scale manufacturing partners to rapidly deploy this new high throughput test around the world.
On 6th April 2020, Avacta confirmed its conditional raising of a further £3.75m (taking its total raise to £5.75m) through an equity placing at 18p/share in response to substantial institutional interest. Along with the newly found and urgent need to respond to calls for a high-throughput COVID-19 antigen test, the new funds are also being put towards the Group’s other key objective, that of completing the Phase I clinical trial of AVA6000 (pro- doxorubicin). Based on anticipated burn for the COVID-19 test strip as detailed above and its existing programmes, TPI estimates Avacta should still hold cash c.£8.0m by its December year end. It will initiate the Phase I trial of its lead asset late in 2020 and initial data will be available within a few months, suggesting the Group is now fully-funded to complete this trial. Beyond the obvious reputational and commercial, albeit presently unquantifiable, short and longer-term opportunities that could emerge from its new partnerships with Cytiva and Adeptrix, such developments represent a major inflection point along with potential for creation of significant value for Avacta, while it also continues to forward its partnered programmes and licensing relationships for its diagnostics reagents.

Avacta Group plc
Avacta has announced its second partnership to exploit the recently generated Affimer binders to the SARS-COV-2 virus in a high-throughput COVID-19 antigen test. This follows the Group’s stated intention to partner its SARS-COV-2 spike protein Affimer reagents with several select companies in order to support antigen test development on multiple diagnostic platforms. This is expected to contribute most effectively to the urgent need for rapid antigen tests to diagnose this coronavirus infection, such that it can be mass produced for rapid, professional screening of large populations and, potentially for self-testing by consumers themselves. This is crucial to limiting and tracking the spread of this disease. The two companies are aiming to have a BAMSTM test ready for clinical validation, regulatory approval and manufacturing in June. Although the full terms of business have not been disclosed, Avacta will receive a royalty on the sales of Adeptrix test kits. As such this represents another important step forward, not only in terms of development of a reputation-building, high- profile new product of global significance, but also in terms of Avacta maximising the near and longer-term commercial opportunities for its platform.
Following on from the Avacta/Cytiva Partnership announced just five weeks ago, this new collaboration with Adeptrix (Beverly, MA, USA) is to develop a high throughput COVID-19 antigen test using Adeptrix’s proprietary bead-assisted mass spectrometry (‘BAMSTM’) platform. The two companies will collaborate in order to develop and manufacture an Affimer-based BAMS coronavirus antigen test that will provide clinicians with a significant expansion of the available testing capacity for COVID-19 infection in hospitals.
Adeptrix’s novel BAMS platform combines enrichment of the sample to improve sensitivity with the power of mass-spectrometry to improve specificity. Hundreds of samples per day can be analysed by a single technician using BAMS, exceeding the capacity of single PCR machine and thereby making it a very attractive high-throughput technique for COVID-19 screening in the clinical setting. The diagnostic test will allow hospitals around the world to utilise their existing installed base of mass spectrometers that are not currently used for COVID-19 testing, thus contributing significantly to the increase in global testing capacity. Significantly also, mass spectrometry can enhance the diagnostic utility of immunoassays, as it is capable of monitoring both existing and emerging viral strains by accurately measuring the molecular components of the virus. BAMS thus provides an ideal multiplexing platform to obtain higher specificity for monitoring COVID-19 infection. Avacta’s own recently developed Affimer reagents that bind the SARS-COV-2 spike protein, will be used to provide the capture and enrichment of the virus particle from the sample which could be saliva, nasopharyngeal swabs or serum.

4 MMs on 112 and several at 117 reacting to early buya

110-112

107-112 at the mo

My 750k showing as a sell. The tech is superb and through poor management commercially means it’s been a tough time but I think corner has been turned. Hopefully we get some more positive commentary with the FY19 results. Outlook/further update on H2 since the last RNS

Same as, I got another 125,000 below so showing as a sell.

They’ve only recently had a raise and covid delayed all results. They’ve increased production at no cost to them and fulfilling backdated orders as well as traction due to covid. Years of missed targets but not I believe they have better direction and will start to finally properly commercialise the superb tech. A long time coming but a gold entry point or time to add IMO.

Bought another 760k at 1.15p which isn’t yet showing.

Cheers pal.

Anyone know how to change the view on this as I have to go into each subject/topic rather than getting one feed?

Apologies if I came across as arsey, Wilson.

It’s so see whether their nubuliser (under trial) should be administered before the results of the C19 test comes back which can take a couple of days (PCR). So they can see if there is an infection at their bedside (not what it is) and administer. Did you read it?!

Yeah far from convincing. From advfn - 11 patients Vs 10 in the control group showed some improvement, but half of both groups were discharged from hospital after 2 weeks. Big deal.

Also -
Even if a treatment shows efficacy, which this doesn't of any significance whatsoever, but let's assume it did.

This in no way diminishes the need to test, so I totally disagree with your premise that any treatment would affect sentiment on a stock that produces tests.

Having a treatment doesn't stop rapid transmission of the virus and therefore doesn't stop the continued need to test repeatedly and at scale.

You'd be better off just stating that you've sold your stock rather than promoting that weak and convoluted argument.

The clear leaders in the space and a great add-on to existing clients so additional revenues (more recurring too?) and an even stronger sales proposition for new ones. Onwards and upwards for both MWG and SKIN.

Yep! Would love to cement 100 today and get to or above 110.

That shouldn’t be 1p just 10 min at home kit!